Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 3, 2016, Pages 539-554

  Sajja, Ravi K ^a   Rahman, Shafiqur ^b   Cucullo, Luca ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

alternative; blood brain barrier; cocaine; Drug abuse; methamphetamine; nicotine; oxidative stress; tight junctions

Indexed keywords

COCAINE; METHAMPHETAMINE; NICOTINE; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT;

BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; CEREBROVASCULAR DISEASE; DISEASE EXACERBATION; DRUG ABUSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NEUROPATHOLOGY; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SMOKING; VIRUS ENCEPHALITIS; ADVERSE EFFECTS; ANIMAL; COMPLICATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; METABOLISM; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; ENCEPHALITIS, VIRAL; HIV; HIV INFECTIONS; HUMANS; METHAMPHETAMINE; NICOTINE; OXIDATIVE STRESS; SMOKING;

EID: 84959432024     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15616978     Document Type: Review

References (150)

1. Herbeck DM, Brecht ML, and Lovinger K. Mortality, causes of death, and health status among methamphetamine users. J Addict Dis 2015; 34: 88-100
2. Yamamoto BK, and Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 2008; 3: 203-217
3. Curtin K, et al. Methamphetamine/amphetamine abuse, and risk of Parkinsons disease in Utah: a populationbased assessment. Drug Alcohol Depend 2015; 146: 30-38
4. Clark KH, Wiley CA, and Bradberry CW. Psychostimulant abuse, and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 2013; 23: 174-188
5. Peraile I, et al. Dopamine transporter down-regulation following repeated cocaine: implications for 3, 4-methylenedioxymethamphetamine-induced acute effects, and long-term neurotoxicity in mice. Br J Pharmacol 2010; 159: 201-211
6. Granado N, et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage, and gliosis in the striatum. Glia 2011; 59: 1850-1863
7. Krasnova IN, Ladenheim B, and Cadet JL. Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway. FASEB J 2005; 19: 851-853
8. Krasnova IN, and Cadet JL. Methamphetamine toxicity, and messengers of death. Brain Res Rev 2009; 60: 379-407
9. Uys JD, Mulholland PJ, and Townsend DM. Glutathione, and redox signaling in substance abuse. Biomed Pharmacother 2014; 68: 799-807
10. Iguchi Y, et al. Repeated exposure of adult rats to transient oxidative stress induces various long-lasting alterations in cognitive, and behavioral functions. PLoS One 2014; 9: e114024
11. Durazzo TC, et al. History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug Alcohol Depend 2014; 142: 262-268
12. Barbosa DJ, et al. Mitochondria: key players in the neurotoxic effects of amphetamines. Arch Toxicol 2015; 89: 1695-1725
13. Walker J, et al. Total antioxidant capacity is significantly lower in cocaine-dependent, and methamphetaminedependent patients relative to normal controls: results from a preliminary study. Hum Psychopharmacol 2014; 29: 537-543
14. Egleton RD, and Abbruscato T. Drug abuse, and the neurovascular unit. Adv Pharmacol 2014; 71: 451-480
15. OShea E, Urrutia A, Green AR, et al. Current preclinical studies on neuroinflammation, and changes in bloodbrain barrier integrity by MDMA, and methamphetamine. Neuropharmacology 2014; 87: 125-134
16. Silva AP, et al. Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis, and blood-brain barrier. Curr Drug Abuse Rev 2010; 3: 239-254
17. Ho EL, Josephson SA, Lee HS, et al. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care 2009; 10: 295-305
18. Polesskaya O, et al. Methamphetamine causes sustained depression in cerebral blood flow. Brain Res 2011; 1373: 91-100
19. Fonseca AC, and Ferro JM. Drug abuse, and stroke. Curr Neurol Neurosci Rep 2013; 13: 325
20. Park K, You J, Du C, et al. Cranial window implantation on mouse cortex to study microvascular change induced by cocaine. Quant Imaging Med Surg 2015; 5: 97-107
21. Mazzone P, et al. Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area. Int J Environ Res Public Health 2010; 7: 4111-4126
22. Kaplan EH, Gottesman RF, Llinas RH, et al. The association between specific substances of abuse, and subcortical intracerebral hemorrhage versus ischemic lacunar infarction. Front Neurol 2014; 5: 174
23. Weaver J, et al. In vivo evidence of methamphetamine induced attenuation of brain tissue oxygenation as measured by EPR oximetry. Toxicol Appl Pharmacol 2014; 275: 73-78
24. Martinez N, Diez-Tejedor E, and Frank A. Vasospasm/thrombus in cerebral ischemia related to cocaine abuse. Stroke 1996; 27: 147-148
25. Montagne A, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296-302
26. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure, and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25
27. Zlokovic BV. The blood-brain barrier in health, and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201
28. Banks WA. The blood-brain barrier in neuroimmunology: tales of separation, and assimilation. Brain Behav Immun 2015; 44: 1-8
29. Hawkins BT, and Davis TP. The blood-brain barrier/neurovascular unit in health, and disease. Pharmacol Rev 2005; 57: 173-185
30. Palmiotti CA, et al. In vitro cerebrovascular modeling in the 21st century: current, and prospective technologies. Pharm Res 2014; 31: 3229-3250
31. Patabendige A, Skinner RA, Morgan L, et al. A detailed method for preparation of a functional, and flexible blood-brain barrier model using porcine brain endothelial cells. Brain Res 2013; 1521: 16-30
32. Stanimirovic DB, Bani-Yaghoub M, Perkins M, et al. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics. Expert Opin Drug Discov 2015; 10: 141-155
33. Bauer HC, Krizbai IA, Bauer H, et al. You Shall Not Pass-tight junctions of the blood brain barrier. Front Neurosci 2014; 8: 392
34. Luissint AC, Artus C, Glacial F, et al. Tight junctions at the blood brain barrier: physiological architecture, and disease-associated dysregulation. Fluids Barriers CNS 2012; 9: 23
35. Loscher W, and Potschka H. Drug resistance in brain diseases, and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602
36. Miller DS, and Cannon RE. Signaling pathways that regulate basal ABC transporter activity at the bloodbrain barrier. Curr Pharm Des 2014; 20: 1463-1471
37. Ohtsuki S, et al. Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics. Expert Rev Proteomics 2014; 11: 303-313
38. Calabria AR, and Shusta EV. Blood-brain barrier genomics, and proteomics: elucidating phenotype, identifying disease targets, and enabling brain drug delivery. Drug Discov Today 2006; 11: 792-799
39. Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol 2005; 30: 57-70
40. Enciu AM, Gherghiceanu M, and Popescu BO. Triggers, and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing, and neurodegeneration. Oxid Med Cell Longev 2013; 297512
41. Lehner C, et al. Oxidative stress, and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal 2011; 15: 1305-1323
42. Freeman LR, and Keller JN. Oxidative stress, and cerebral endothelial cells: regulation of the blood-brain-barrier, and antioxidant based interventions. Biochim Biophys Acta 2012; 1822: 822-829
43. Naik P, et al. Oxidative, and pro-inflammatory impact of regular, and denicotinized cigarettes on blood brain barrier endothelial cells: is smoking reduced or nicotine-free products really safe?. BMC Neurosci 2014; 15: 51
44. Sajja RK, Prasad S, and Cucullo L. Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line. Fluids Barriers CNS 2014; 11: 8
45. Sajja RK, Green KN, and Cucullo L. Altered nrf2 signaling mediates hypoglycemia-induced blood-brain barrier endothelial dysfunction in vitro. PLoS One 2015; 10: e0122358
46. Wang Y, et al. Methamphetamine potentiates ischemia/reperfusion insults after transient middle cerebral artery ligation. Stroke 2001; 32: 775-782
47. Ohta K, Mori M, Yoritaka A, et al. Delayed ischemic stroke associated with methamphetamine use. J Emerg Med 2005; 28: 165-167
48. Rothrock JF, Rubenstein R, and Lyden PD. Ischemic stroke associated with methamphetamine inhalation. Neurology 1988; 38: 589-592
49. Kousik SM, Graves SM, Napier TC, et al. Methamphetamine-induced vascular changes lead to striatal hypoxia, and dopamine reduction. Neuroreport 2011; 22: 923-928
50. Chung YS, Peterson BS, Yoon SJ, et al. In vivo evidence for long-term CNS toxicity, associated with chronic binge use of methamphetamine. Drug Alcohol Depend 2010; 111: 155-160
51. Dietrich JB. Alteration of blood-brain barrier function by methamphetamine, and cocaine. Cell Tissue Res 2009; 336: 385-392
52. Asanuma M, Miyazaki I, Higashi Y, et al. Specific gene expression, and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann NY Acad Sci 2004; 1025: 69-75
53. Sharma HS, and Ali SF. Alterations in blood-brain barrier function by morphine, and methamphetamine. Ann NY Acad Sci 2006; 1074: 198-224
54. Carlsson C, and Johansson BB. Blood-brain barrier dysfunction after amphetamine administration in rats. Acta Neuropathol 1978; 41: 125-129
55. Rakic LM, et al. Effects of sensory-motor cortical lesions on blood-brain permeability in guinea pigs. Metab Brain Dis 1989; 4: 9-15
56. Kousik SM, Napier TC, and Carvey PM. The effects of psychostimulant drugs on blood brain barrier function, and neuroinflammation. Front Pharmacol 2012; 3: 121
57. Bowyer JF, and Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006; 60: 521-532
58. Bowyer JF, Thomas M, Schmued LC, et al. Brain regionspecific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier. Ann NY Acad Sci 2008; 1139: 127-139
59. Martins T, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins, and matrix metalloproteinase-9. Brain Res 2011; 1411: 28-40
60. ElAli A, et al. Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1, and ABCC1 on cerebral microvessels after methamphetamine intoxication. Stroke 2012; 43: 1647-1653
61. Rahman S. Drug addiction, and brain targets: from preclinical research to pharmacotherapy. CNS Neurol Disord Drug Targets 2008; 7: 391-392
62. Hwang J, et al. Decreased cerebral blood flow of the right anterior cingulate cortex in long-term, and short-term abstinent methamphetamine users. Drug Alcohol Depend 2006; 82: 177-181
63. Zhang X, Banerjee A, Banks WA, et al. N-acetylcysteine amide protects against methamphetamine-induced oxidative stress, and neurotoxicity in immortalized human brain endothelial cells. Brain Res 2009; 1275: 87-95
64. Ramirez SH, et al. Methamphetamine disrupts bloodbrain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 2009; 29: 1933-1945
65. Mahajan SD, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008; 1203: 133-148
66. Banerjee A, Zhang X, Manda KR, et al. HIV proteins (gp120, and Tat), and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med 2010; 48: 1388-1398
67. Toborek M, et al. Voluntary exercise protects against methamphetamine-induced oxidative stress in brain microvasculature, and disruption of the blood-brain barrier. Mol Neurodegener 2013; 8: 22
68. Coelho-Santos V, et al. The TNF-alpha/NF-kappaB signaling pathway has a key role in methamphetamineinduced blood-brain barrier dysfunction. J Cereb Blood Flow Metab 2015; 35: 1260-1271
69. Abdul Muneer PM, Alikunju S, Szlachetka AM, et al. Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol Neurodegener 2011; 6: 23
70. Park M, Hennig B, and Toborek M. Methamphetamine alters occludin expression via NADPH oxidase-induced oxidative insult, and intact caveolae. J Cell Mol Med 2012; 16: 362-375
71. Martins T, et al. Methamphetamine-induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells. Neuropharmacology 2013; 65: 74-82
72. Turowski P, and Kenny BA. The blood-brain barrier, and methamphetamine: open sesame?. Front Neurosci 2015; 9: 156
73. Park M, Kim HJ, Lim B, et al. Methamphetamineinduced occludin endocytosis is mediated by the Arp2/3 complex-regulated actin rearrangement. J Biol Chem 2013; 288: 33324-33334
74. Rubio-Araiz A, et al. 3, 4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors. Int J Neuropsychopharmacol 2014; 17: 1243-1255
75. Urrutia A, et al. A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine. Neurobiol Dis 2013; 50: 49-58
76. Lee YW, Hennig B, Yao J, et al. Methamphetamine induces AP-1, and NF-kappaB binding, and transactivation in human brain endothelial cells. J Neurosci Res 2001; 66: 583-591
77. Forster C, et al. Differential effects of hydrocortisone, and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 2008; 586: 1937-1949
78. Rom S, et al. Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic, and neuroinflammatory conditions. J Cereb Blood Flow Metab 2015; 35: 28-36
79. Rochfort KD, Collins LE, Murphy RP, et al. Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidasedependent ROS generation: consequences for interendothelial adherens, and tight junctions. PLoS One 2014; 9: e101815
80. Eugenin EA, Greco JM, Frases S, et al. Methamphetamine alters blood brain barrier protein expression in mice, facilitating central nervous system infection by neurotropic Cryptococcus neoformans. J Infect Dis 2013; 208: 699-704
81. Malaplate-Armand C, et al. Effect of acute, and chronic psychostimulant drugs on redox status, AP-1 activation, and pro-enkephalin mRNA in the human astrocyte-like U373 MG cells. Neuropharmacology 2005; 48: 673-684
82. Zhang Y, et al. Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression. J Neuroinflammation 2015; 12: 29
83. Shah A, Silverstein PS, Singh DP, et al. Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling, and NF-kappaB pathway in methamphetamine-mediated increase in IL-6, and IL-8 expression in astrocytes. J Neuroinflammation 2012; 9: 52
84. Yang YM, Shang DS, Zhao WD, et al. Microglial TNFalpha-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration. Neurochem Res 2013; 38: 2295-2304
85. Fiala M, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 2005; 11: 281-291
86. Gan X, et al. Cocaine enhances brain endothelial adhesion molecules, and leukocyte migration. Clin Immunol 1999; 91: 68-76
87. Ren H, et al. Cocaine-induced cortical microischemia in the rodent brain: clinical implications. Mol Psychiatry 2012; 17: 1017-1025
88. Daras M, Tuchman AJ, and Marks S. Central nervous system infarction related to cocaine abuse. Stroke 1991; 22: 1320-1325
89. Sharma HS, Muresanu D, Sharma A, et al. Cocaineinduced breakdown of the blood-brain barrier, and neurotoxicity. Int Rev Neurobiol 2009; 88: 297-334
90. Kumar M. Cocaine, and the blood-brain-barrier. Blood 2011; 117: 2303
91. Fiala M, et al. Cocaine enhances monocyte migration across the blood-brain barrier Cocaines connection to AIDS dementia, and vasculitis?. Adv Exp Med Biol 1998; 437: 199-205
92. Zhang L, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4: 619-626
93. Dhillon NK, et al. Cocaine-mediated alteration in tight junction protein expression, and modulation of CCL2/CCR2 axis across the blood-brain barrier: implications for HIV-dementia. J Neuroimmune Pharmacol 2008; 3: 52-56
94. Gandhi N, et al. Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein, and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder. J Neurovirol 2010; 16: 294-305
95. Yao H, Duan M, and Buch S. Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood 2011; 117: 2538-2547
96. Yao H, et al. Cocaine hijacks sigma1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion, and migration in the CNS. J Neurosci 2011; 31: 5942-5955
97. Yang L, et al. Role of sigma receptor in cocaine-mediated induction of glial fibrillary acidic protein: implications for HAND. Mol Neurobiol, Epub ahead of print 29 January 2015. DOI: 10.1007/s12035-015-9094-5
98. Fattore L, et al. Astroglial in vivo response to cocaine in mouse dentate gyrus: a quantitative, and qualitative analysis by confocal microscopy. Neuroscience 2002; 110: 1-6
99. Buch S, et al. Cocaine, and HIV-1 interplay in CNS: cellular, and molecular mechanisms. Curr HIV Res 2012; 10: 425-428
100. Badisa RB, et al. N-acetyl cysteine mitigates the acute effects of cocaine-induced toxicity in astroglia-like cells. PLoS One 2015; 10: e0114285
101. Cearley CN, Blindheim K, Sorg BA, et al. Acute cocaine increases interleukin-1beta mRNA, and immunoreactive cells in the cortex, and nucleus accumbens. Neurochem Res 2011; 36: 686-692
102. OCarroll SJ, et al. Pro-inflammatory TNFalpha, and IL-1beta differentially regulate the inflammatory phenotype of brain microvascular endothelial cells. J Neuroinflammation 2015; 12: 131
103. Yao H, et al. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 2010; 115: 4951-4962
104. Barnoya J, and Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111: 2684-2698
105. Frey P, and Waters DD. Tobacco smoke, and cardiovascular risk: a call for continued efforts to reduce exposure. Curr Opin Cardiol 2011; 26: 424-428
106. Messner B, and Bernhard D. Smoking, and cardiovascular disease: mechanisms of endothelial dysfunction, and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34: 509-515
107. Boms N, et al. Effect of smoking cessation on visually evoked cerebral blood flow response in healthy volunteers. J Vasc Res 2010; 47: 214-220
108. Cao L, Xu CB, Zhang Y, et al. Secondhand smoke exposure induces Raf/ERK/MAPK-mediated upregulation of cerebrovascular endothelin ETA receptors. BMC Neurosci 2011; 12: 109
109. Luchsinger JA, et al. Aggregation of vascular risk factors, and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551
110. Peters R, et al. Smoking, dementia, and cognitive decline in the elderly, a systematic review. BMC Geriatr 2008; 8: 36
111. Hawkins BT, Brown RC, and Davis TP. Smoking, and ischemic stroke: a role for nicotine?. Trends Pharmacol Sci 2002; 23: 78-82
112. Sajja RK, Naik P, and Cucullo L. Differential cerebrovascular toxicity of various tobacco products: a regulatory perspective. J Pharmacovigil 2015; 3: 1
113. Hossain M, et al. Tobacco smoke: a critical etiological factor for vascular impairment at the blood-brain barrier. Brain Res 2009; 1287: 192-205
114. Hossain M, Mazzone P, Tierney W, et al. In vitro assessment of tobacco smoke toxicity at the BBB: do antioxidant supplements have a protective role?. BMC Neurosci 2011; 12: 92
115. Naik P, Sajja RK, Prasad S, et al. Effect of full flavor, and denicotinized cigarettes exposure on the brain microvascular endothelium: a microarray-based gene expression study using a human immortalized BBB endothelial cell line. BMC Neurosci 2015; 16: 38
116. Abbruscato TJ, Lopez SP, Mark KS, et al. Nicotine, and cotinine modulate cerebral microvascular permeability, and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci 2002; 91: 2525-2538
117. Hawkins BT, et al. Nicotine increases in vivo bloodbrain barrier permeability, and alters cerebral microvascular tight junction protein distribution. Brain Res 2004; 1027: 48-58
118. Hutamekalin P, et al. Effect of nicotine, and polyaromtic hydrocarbons on cerebral endothelial cells. Cell Biol Int 2008; 32: 198-209
119. Manda VK, Mittapalli RK, Bohn KA, et al. Nicotine, and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 2010; 115: 1495-1507
120. Wang L, McComb JG, Weiss MH, et al. Nicotine downregulates alpha 2 isoform of Na, K-ATPase at the bloodbrain barrier, and brain in rats. Biochem Biophys Res Commun 1994; 199: 1422-1427
121. Manda VK, Mittapalli RK, Geldenhuys WJ, et al. Chronic exposure to nicotine, and saquinavir decreases endothelial Notch-4 expression, and disrupts bloodbrain barrier integrity. J Neurochem 2010; 115: 515-525
122. Yong T, Zheng MQ, and Linthicum DS. Nicotine induces leukocyte rolling, and adhesion in the cerebral microcirculation of the mouse. J Neuroimmunol 1997; 80: 158-164
123. Hawkins BT, Egleton RD, and Davis TP. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 2005; 289: H212-H219
124. Abbruscato TJ, Lopez SP, Roder K, et al. Regulation of blood-brain barrier Na, K, 2Cl-cotransporter through phosphorylation during in vitro stroke conditions, and nicotine exposure. J Pharmacol Exp Ther 2004; 310: 459-468
125. Paulson JR, et al. Tobacco smoke chemicals attenuate brain-to-blood potassium transport mediated by the Na, K, 2Cl-cotransporter during hypoxia-reoxygenation. J Pharmacol Exp Ther 2006; 316: 248-254
126. Wang L, Kittaka M, Sun N, et al. Chronic nicotine treatment enhances focal ischemic brain injury, and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cereb Blood Flow Metab 1997; 17: 136-146
127. Bradford ST, Stamatovic SM, Dondeti RS, et al. Nicotine aggravates the brain postischemic inflammatory response. Am J Physiol Heart Circ Physiol 2011; 300: H1518-H1529
128. Chen JL, et al. Nicotine raises the influx of permeable solutes across the rat blood-brain barrier with little or no capillary recruitment. J Cereb Blood Flow Metab 1995; 15: 687-698
129. Uzum G, Diler AS, and Ziylan YZ. Chronic nicotine pretreatment protects the blood-brain barrier against nicotine-induced seizures in the rat. Pharmacol Res 1999; 40: 263-269
130. Canis M, et al. Increased densities of monocarboxylate transport protein MCT1 after chronic administration of nicotine in rat brain. Neurosci Res 2009; 64: 429-435
131. Duelli R, Staudt R, Grunwald F, et al. Increase of glucose transporter densities (Glut1, and Glut3) during chronic administration of nicotine in rat brain. Brain Res 1998; 782: 36-42
132. Elbirt D, et al. HIV-associated neurocognitive disorders (HAND). Isr Med Assoc J 2015; 17: 54-59
133. Brew BJ, and Chan P. Update on HIV dementia, and HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep 2014; 14: 468
134. Conant K, et al. Human immunodeficiency virus type 1 Tat, and methamphetamine affect the release, and activation of matrix-degrading proteinases. J Neurovirol 2004; 10: 21-28
135. Nath A, Maragos WF, Avison MJ, et al. Acceleration of HIV dementia with methamphetamine, and cocaine. J Neurovirol 2001; 7: 66-71
136. Niu F, Yao H, Zhang W, et al. Tat 101-mediated enhancement of brain pericyte migration involves platelet-derived growth factor subunit B homodimer: implications for human immunodeficiency virus-associated neurocognitive disorders. J Neurosci 2014; 34: 11812-11825
137. Sharma A, Hu XT, Napier TC, et al. Methamphetamine, and HIV-1 Tat down regulate beta-catenin signaling: implications for methampetamine abuse, and HIV-1 co-morbidity. J Neuroimmune Pharmacol 2011; 6: 597-607
138. Shah A, Silverstein PS, Kumar S, et al. Synergistic cooperation between methamphetamine, and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytes. PLoS One 2012; 7: e52060
139. Yang Y, Yao H, Lu Y, et al. Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PLoS One 2010; 5: e13427
140. OPhelan K, et al. Impact of methamphetamine on regional metabolism, and cerebral blood flow after traumatic brain injury. Neurocrit Care 2013; 19: 183-191
141. Kim H, et al. Risk factors for early hemorrhagic progression after traumatic brain injury: a focus on lipid profile. J Neurotrauma 2015; 32: 950-955
142. Gold MS, et al. Methamphetamine-and traumainduced brain injuries: comparative cellular, and molecular neurobiological substrates. Biol Psychiatry 2009; 66: 118-127
143. Tao X, et al. Protective actions of PJ34, a poly(ADPribose) polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice. Neuroscience 2015; 291: 26-36
144. Abdul-Muneer PM, Chandra N, and Haorah J. Interactions of oxidative stress, and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol 2015; 51: 966-979
145. Glushakova OY, Johnson D, and Hayes RL. Delayed increases in microvascular pathology after experimental traumatic brain injury are associated with prolonged inflammation, blood-brain barrier disruption, and progressive white matter damage. J Neurotrauma 2014; 31: 1180-1193
146. Prasad S, et al. Impact of cigarette smoke extract, and hyperglycemic conditions on blood-brain barrier endothelial cells. Fluids Barriers CNS 2015; 12: 18
147. Alfieri A, et al. Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 2011; 589: 4125-4136
148. Sandberg M, Patil J, DAngelo B, et al. NRF2-regulation in brain health, and disease: implication of cerebral inflammation. Neuropharmacology 2014; 79: 298-306
149. Jang EY, et al. Involvement of reactive oxygen species in cocaine-taking behaviors in rats. Addict Biol 2015; 20: 663-675
150. Loftis JM, and Janowsky A. Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol 2014; 118: 165-197